Hokkaido University Collection of Scholarly and Academic Papers >
Global Institution for Collaborative Research and Education : GI-CoRE >
Peer-reviewed Journal Articles, etc >
Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice
This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Title: | Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice |
Authors: | Nakatsukasa, Akihiro Browse this author | Kuruma, Koji Browse this author | Okamatsu, Masatoshi Browse this author →KAKEN DB | Hiono, Takahiro Browse this author | Suzuki, Mizuho Browse this author | Matsuno, Keita Browse this author →KAKEN DB | Kida, Hiroshi Browse this author →KAKEN DB | Oyamada, Takayoshi Browse this author | Sakoda, Yoshihiro Browse this author →KAKEN DB |
Keywords: | Vaccine | Influenza | Dissolving microneedle | Transdermal vaccination | Whole virus particle | Split virion |
Issue Date: | 15-May-2017 |
Publisher: | Elsevier |
Journal Title: | Vaccine |
Volume: | 35 |
Issue: | 21 |
Start Page: | 2855 |
End Page: | 2861 |
Publisher DOI: | 10.1016/j.vaccine.2017.04.009 |
PMID: | 28431812 |
Abstract: | Transdermal vaccination using a microneedle (MN) confers enhanced immunity compared with subcutaneous (SC) vaccination. Here we developed a novel dissolving MN patch for the influenza vaccine. The potencies of split virion and whole virus particle (WVP) vaccines prepared from A/Puerto Rico/8/1934 (H1N1) and A/duck/Hokkaido/Vac-3/2007 (H5N1), respectively, were evaluated. MN vaccination induced higher neutralizing antibody responses than SC vaccination in mice. Moreover, MN vaccination with a lower dose of antigens conferred protective immunity against lethal challenges of influenza viruses than SC vaccination in mice. These results suggest that the WVP vaccines administered using MN are an effective combination for influenza vaccine to be further validated in humans.Previous article in issue |
Rights: | © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/70216 |
Appears in Collections: | 国際連携研究教育局 : GI-CoRE (Global Institution for Collaborative Research and Education : GI-CoRE) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 迫田 義博
|